Bridge Biotherapeutics announced that it received notice from the U.S. Food and Drug Administration that it may proceed with the first-in-human study of BBT-207, which has the potential to be a mutant selective and broad-spectrum fourth-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor for the treatment of non-small cell lung cancer.
